<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133131</url>
  </required_header>
  <id_info>
    <org_study_id>5172-074</org_study_id>
    <nct_id>NCT02133131</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)</brief_title>
  <official_title>A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of grazoprevir (MK-5172) + elbasvir (MK-8742) and sofosbuvir (SOF) in
      treatment-naive participants with chronic hepatitis C (HCV) genotype (GT) 1 or GT3. The
      objective is to determine the proportion of participants achieving sustained virologic
      response 12 weeks after ending study treatment (SVR12).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, single-center, multiple-arm investigation of a fixed-dose
      combination [FDC] of grazoprevir 100mg and elbasvir 50mg, and SOF 400mg, in treatment-naive
      participants with chronic HCV GT1 or GT3. The impact of study treatment regimens of varying
      duration on SVR12 (undetectable HCV ribonucleic acid [RNA] 12 weeks after ending study
      treatment) in cirrhotic (C) participants and non-cirrhotic (NC) participants will be
      determined (Part A). Any HCV GT1 participant from study Arms 1-4 in Part A who experienced
      virologic relapse will be offered retreatment consisting of 12 additional weeks of treatment
      with MK-5172/MK-8742 + SOF + ribavirin and 24 weeks of follow-up in Part B.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving SVR12</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing at least 1 adverse event (AE)</measure>
    <time_frame>Up to Week 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study therapy due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR4</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 4wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 4 weeks (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 6 weeks (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 6 weeks (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 8 weeks (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 8 weeks (n=15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 12 weeks (n=15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:C Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/Elbasvir (100mg/50mg) + SOF 400mg for 12 weeks (n=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir/Elbasvir FDC</intervention_name>
    <description>FDC tablet (100mg grazoprevir/50mg elbasvir), once daily by mouth</description>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 4wk</arm_group_label>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
    <arm_group_label>GT3:C Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
    <other_name>MK-5172A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400mg tablet, once daily by mouth</description>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 4wk</arm_group_label>
    <arm_group_label>GT1:NC Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
    <arm_group_label>GT3:C Grazoprevir/Elbasvir+SOF 12wk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has HCV RNA ≥10,000 IU/mL in peripheral blood at the time of screening

          -  has documented chronic HCV GT1 or GT3 infection

          -  has either negative or positive history of liver cirrhosis based on liver biopsy,
             Fibroscan, or FibroSure ® (Fibrotest®)

          -  is treatment naïve to all anti-HCV treatment

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or
             human immunodeficiency virus

          -  has a history of malignancy ≤5 years prior to signing informed consent, or is under
             evaluation for other active or suspected malignancy

          -  has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has clinically-relevant drug or alcohol abuse within 12 months of screening

          -  has any of the following conditions: organ transplants other than cornea and hair,
             poor venous access that precludes routine peripheral blood sampling, history of
             gastric surgery or malabsorption disorders, or any medical condition requiring, or
             likely to require, chronic systemic administration of corticosteroids during the
             course of the trial

          -  has a history of chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 19, 2015</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
